Teva Pharmaceutical Industries (LTS:0LER) Accumulated Depreciation: $ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LER Teva Pharmaceutical Industries Ltd LTS:0LER
39 GF Score
Price $37.10
GF Value $18.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Accumulated Depreciation?

Teva Pharmaceutical Industries LTS:0LER +2.20% 39 Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus rates LTS:0LER with a GF Score™ of 39/100 and a GF Value™ of $18.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Teva Pharmaceutical Industries's annual accumulated depreciation declined from Dec. 2023 ($-5,637 Mil) to Dec. 2024 ($-4,410 Mil) but then increased from Dec. 2024 ($-4,410 Mil) to Dec. 2025 ($-4,728 Mil).

Teva Pharmaceutical Industries Accumulated Depreciation Related Terms

Teva Pharmaceutical Industries Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Accumulated Depreciation Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,241.07 -5,518.07 -5,637.03 -4,410.00 -4,727.93

Teva Pharmaceutical Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
LTS:0LER
39GF Score
Teva Pharmaceutical Industries Ltd LTS:0LER
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $ Mil mean?
Teva Pharmaceutical Industries (LTS:0LER) has a Accumulated Depreciation of $ Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Accumulated Depreciation too high?
Teva Pharmaceutical Industries' current Accumulated Depreciation is $ Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Accumulated Depreciation compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Accumulated Depreciation of $ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Accumulated Depreciation is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (LTS:0LER) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.05, compared to a current price of $37.10 — trading 105.5% above its estimated fair value. The current Accumulated Depreciation is $ Mil. Teva Pharmaceutical Industries' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Teva Pharmaceutical Industries (LTS:0LER), the current Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (LTS:0LER) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of $37.10 is trading 105.5% above its estimated GF Value™ of $18.05. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for LTS:0LER:

  • Accumulated Depreciation: $ Mil
  • GF Value™: $18.05 vs. price of $37.10 (105.5% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the LTS:0LER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
39GF Score

Get the complete analysis for LTS:0LER

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.10
Price
$18.05
GF Value